Introduction
Chemotherapy is an effective standard treatment for gynecologic malignancy. Despite the usefulness and efficacy of chemotherapy, it is still associated with numerous side effects, especially chemotherapy-induced nausea and vomiting (CINV). CINV is one of the most common adverse effects and leads to significant morbidity and deterioration of patients’ quality of life.1 As a consequence, noncompliance to chemotherapy treatment can be frequently observed.2,3
CINV can be divided into five different phases: The acute phase is defined as CINV occurring within 24 h post chemotherapy, delayed phase is defined as CINV occurring within 24–120 h and may last 6–7 days, anticipatory phase is when patients have CINV prior to administration of future chemotherapy, breakthrough phase is when patients have CINV within 5 days of prophylactic antiemetic agents, and refractory phase is when CINV occurs in subsequent chemotherapy cycles following prior failure of prophylactic treatment.4 Delayed phase is more common and severe than the other phases manner and is resistant to antiemetic treatment.5
According to NCCN guidelines, standard antiemetic agents for patients receiving moderate and high emetogenic chemotherapy include 5-HT3 antagonists, dexamethasone, NK1 RAs, and olanzapine. However, NK1 RAs and olanzapine were added for patients receiving high emetic risk chemotherapy. Platinum-based chemotherapy (cisplatin and carboplatin) were the backbone of chemotherapy…
Original Author Link click here to read complete story..
